Of note, efficient blockade of IL36R is already available with the monoclonal antibody spesolimab, as evidenced by the therapeutic success as approved therapy in patients with generalized pustular psoriasis (GPP). The gene discussed is IL1RL2; the disease is psoriasis 14, pustular.